Last update April 25, 2022
Very Low Risk
H2-type histamine receptor antagonist with similar action than cimetidine. Indicated in the treatment of gastric and/or duodenal ulcer and gastroesophageal reflux disease. oral or intravenous administration.
It is excreted in breast milk in clinically non-significant amount, much less than the dose administered to newborns and infants with gastroesophageal reflux disorders. (Wang 2011, Courtney 1988)
It is used in Pediatrics, even in small infants. (Orenstein 2003)
Although it does not affect prolactin secretion (Corinaldesi 1987, Chremos1986, Smith 1985), there have been several cases of galactorrhea; still unknown whether it is due to Famotidine itself or to gastroesophageal reflux. (Güven 1995, Delpre 1993)
Famotidine and Nizatidine are excreted into milk but in less proportion than Cimetidine or Ranitidine, which have been proposed as alternative to during lactation. (Rowe 2013, Nice 2000, Hagemann 1998, Lee 1993)
Several medical societies, experts and expert consensus, consider the use of this medication to be safe or very probably safe during breastfeeding. (Hale, Briggs 2015, Schaefer 2015, Rowe 2013, Mahadevan 2006, Richter 2005, Nice 2000, Lee 1993)
We do not have alternatives for Фамотидин since it is relatively safe.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.